AI
RGLS

Atom Investors’s Regulus Therapeutics RGLS Stock Holding History

Atom Investors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,723
Closed -$526K – 315
2021
Q1 		$526K Buy
+33,723
New +$499K 0.09% 151

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atom Investors's RGLS Position: Q2 2021 in Review

Atom Investors sold out of Regulus Therapeutics (RGLS) in Q2 2021, closing a stake of 33,723 shares — an estimated $526K sold.

Atom Investors first reported a position in RGLS in Q1 2021 and held it in 1 quarter. The position peaked at $526K in Q1 2021. 44 funds tracked by Wall St. Rank hold RGLS as of Q2 2021.

  • Atom Investors reported no remaining Regulus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Atom Investors sold 33,723 Regulus Therapeutics shares in Q2 2021, an estimated $526K.
  • Atom Investors first reported a position in Regulus Therapeutics in Q1 2021 and held it in 1 quarter.
  • Atom Investors's Regulus Therapeutics position peaked at $526K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2021.

Based on Atom Investors's 13F filing for Q2 2021, filed 16 Aug 2021.